Phase 2
Completed N=10
Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)
Source: ClinicalTrials.gov NCT02629822 ↗Enrolled (actual)
10
Serious AEs
6.3%
Results posted
Dec 2019
Primary outcomePrimary: Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 48 — 100.0 Percentage of Participants
Summary
The primary objectives of this study are to evaluate the antiretroviral activity and the safety/tolerability of open-label doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF; MK-1439A; DELSTRIGO™) consisting of a single fixed-dose combination (FDC) tablet of DOR/3TC/TDF 100 mg/300 mg/300 mg in treatment-naïve HIV-1 infected participants with select non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted resistance-associated mutations.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 48 |
100.0 | — |
| PRIMARY Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 48 |
90.0 | — |
| PRIMARY Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 48. |
0.0 | — |
| PRIMARY Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 96 |
90.0 | — |
| PRIMARY Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 96 |
0.0 | — |
| SECONDARY Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 96 |
100.0 | — |
| SECONDARY Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <40 Copies/mL of Plasma at Week 48 |
100.0 | — |
| SECONDARY Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <40 Copies/mL of Plasma at Week 96 |
100.0 | — |
| SECONDARY Change From Baseline in CD4 Cell Count at Week 48 |
409; 132 | — |
| SECONDARY Change From Baseline in CD4 Cell Count at Week 96 |
437; 153 | — |
| SECONDARY Time to Loss of Virologic Response |
166 | — |
Eligibility Criteria
Inclusion Criteria
- Is HIV-1 positive within 45 days prior to the treatment phase of this study, and have HIV treatment indicated based on physician assessment.
- Is naïve to antiretroviral therapy (ART) including investigational antiretroviral agents.
- Prior to screening, have had a genotype performed confirming the presence of only one of the following NNRTI mutations: K103N, Y181C, or G190A.
- Is considered clinically stable with no signs or symptoms of active infection at time of entry into the study (i.e. clinical status and all chronic medications should be unchanged for at least 2 weeks prior to the start of treatment in this study).
- Is highly unlikely to become pregnant or to impregnate a partner
Exclusion Criteria
- Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
- Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1, including, but not limited to, adefovir, tenofovir, entecavir, emtricitabine, or lamivudine.
- Has documented or known resistance to study drugs (doravirine, lamivudine, and/or tenofovir)
- Has participated or anticipates participating in a study with an investigational compound/device within 30 days prior to signing informed consent
- Has any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppressant drugs during the course of the trial.
- Requires or anticipates requiring any of the prohibited medications
- Has significant hypersensitivity or other contraindication to any of the components of the study drug
- Has a current (active) diagnosis of acute hepatitis due to any cause
- Has evidence of decompensated liver disease or has liver cirrhosis and a Child-Pugh Class C score or Pugh-Turcotte (CPT) score > 9
- Is pregnant, breastfeeding, or expecting to conceive
- Is female and expecting to donate eggs, or is male and is expecting to donate sperm at any time during the study
Data sourced from ClinicalTrials.gov (NCT02629822). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.